Suxamethonium: a new look at pretreatment

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Suxamethonium is a common neuromuscular blocking agent used for rapid sequence intubation.
• Pretreatment protocols aim to mitigate adverse effects of suxamethonium, such as fasciculations and myalgia.
• The efficacy of different pretreatment agents requires further investigation.

Purpose of the Study:

• To evaluate the effects of suxamethonium and gallamine pretreatment on neuromuscular transmission.
• To compare the impact of these pretreatments on the efficacy of a subsequent suxamethonium dose for intubation.

Main Methods:

• Fifty patients were randomized to receive either 10 mg suxamethonium or 20 mg gallamine as pretreatment.
• A subsequent dose of 1 mg/kg suxamethonium was administered for intubation.
• Neuromuscular blockade was assessed by monitoring the mechanical response of the adductor pollicis muscle to train-of-four stimulation.

Main Results:

• Suxamethonium pretreatment induced fasciculations in 25% of patients.
• Significant neuromuscular blockade was observed in 16 out of 25 patients pretreated with suxamethonium.
• Gallamine pretreatment diminished the neuromuscular blocking effect of the intubating suxamethonium dose, increasing intubation difficulty.

Conclusions:

• Suxamethonium pretreatment can cause significant neuromuscular blockade and fasciculations.
• Gallamine pretreatment antagonizes the neuromuscular blocking effects of suxamethonium, potentially hindering intubation.
• Alternative pretreatment strategies may be necessary to optimize neuromuscular blockade for intubation.